P
PleoPharma
Develops a treatment to help meet the growing demand of a significant medical condition
About PleoPharma
PleoPharma is a pharmaceutical development company dedicated to creating safe and effective FDA-approved treatments for substance use disorders, particularly where no current therapies exist. The company operates in the healthcare and pharmaceutical market, targeting individuals suffering from conditions such as cannabis use disorder (CUD). PleoPharma's business model revolves around research and development, clinical trials, and eventual commercialization of their pharmaceutical products. The company collaborates with industry partners, healthcare providers, researchers, and investors to advance their mission. Revenue is generated through the development and sale of FDA-approved medications, as well as potential partnerships and licensing agreements. PleoPharma's lead program has successfully completed Phase 2 clinical trials, receiving enthusiastic support from the medical community. The company is committed to high moral and ethical standards, ensuring that their treatments meet the growing demand for effective solutions to significant medical conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Phoenixville, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 51.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Aug 2026 | $6.5M | — | National Institute on Drug Abuse (NIDA) | ↗ |
| SERIES B✓Equity / VC | Oct 2025 | $36M | $144M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for PleoPharma is 1.1K monthly website visits, up 52.8% over the last three months. PleoPharma's team grew 9.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute on Drug Abuse (NIDA)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PleoPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PleoPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.